Image

Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training

Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training

Recruiting
40-85 years
All
Phase N/A

Powered by AI

Overview

The rates of cognitive decline and dementia after stroke are disproportionately high. Strategies that can protect the brain early after the stroke event could reduce the future risk of cognitive decline and dementia in these patients. Although physical exercise is usually recommended after stroke, there is very little information about the protective effect of exercise implemented in early stages of recovery as a potential protective measure against cognitive decline and dementia risk in these patients. This study will investigate the effect of a multimodal exercise intervention implemented early after the stroke event on cognition and on a selected group of markers that can predict cognitive decline and dementia risk.

Description

Background: Post-stroke cognitive impairment is very prevalent and a major contributor to disability. Suffering a stroke doubles the risk of dementia, which can develop very quickly after the stroke event. Introduced in early stages of stroke recovery, physical exercise could mitigate the neurodegeneration process triggered by the stroke event, reduce cognitive decline, and prevent the development or slow down the progression of dementia. However, there is still not enough evidence to recommend the implementation of exercise as an effective countermeasure to protect the brain and preserve cognition in these patients.

Aims: To compare the effects of 12 weeks of multimodal training and an active comparator condition implemented in subacute stroke on cognition and imaging and blood biomarkers associated with accelerated cognitive decline and dementia risk.

Design: This is a two-group staggered entry parallel single blind multisite adaptive RCT that will compare one group undergoing 12 weeks of multimodal training and a group undergoing 12 weeks of balance, toning, and stretching training. Assessments will be performed by blinded assessors at baseline (T0), after each 12-week intervention (T1) as well as 6 (T2) and 12 (T3) months follow-up. Cognition will be assessed with the Alzheimer Disease Assessment Methodology Scale-Cognitive Scale 13 Plus. Cerebral blood flow will be assessed with magnetic resonance imaging (MRI) and blood brain barrier permeability with a novel arterial spin labeling MRI technique that does not require contrast agent. Biomarkers of inflammation, neurodegeneration and axonal injury, which are associated with accelerated cognitive decline and dementia, will be assessed with blood assays. Cerebral Blood Velocity will be assessed using Transcranial Doppler Ultrasound. Other outcome measures include muscle strength, self-reported cognitive function, functional mobility, gait speed, cardiorespiratory fitness, neuropsychological status, body composition and anthropometrics, health related quality of life, fatigue and health care resource utilization.

Expertise: Our team includes a diverse group of physical therapists, kinesiologists, neurologists, neuroscientists, neuroimmunologists, physicists, biostatisticians and clinicians at different career stages. We have expertise in exercise RCTs post-stroke and the development of novel imaging and blood predictive biomarkers of dementia risk.

Expected outcomes: We expect that multimodal training will be more effective at improving cognition and that differences between groups will persist 12 months after training, indicating a long-lasting protective effect of multimodal training when introduced in early stages of stroke recovery. We also expect that, compared with the control condition, multimodal training will increase more significantly cerebral blood flow and reduce blood brain barrier permeability as well as the concentration of blood biomarkers of inflammation, neurodegeneration, and axonal injury. We anticipate that the identification of associations between changes in biomarkers and cognition will provide important insights about the mechanisms by which exercise can protect the brain against early neurodegeneration post-stroke.

Significance: Patients with stroke have identified the development of interventions to reduce cognitive dysfunction as the most important problem that research must address. However, cognitive post- stroke impairment is commonly neglected and there is a lack of interventions specifically designed to mitigate this problem. This project will determine if exercise implemented in early stages of recovery can reduce the burden of accelerated cognitive decline and dementia risk in these patients.

Eligibility

Inclusion Criteria:

  • have had a first-ever ischemic/hemorrhagic stroke confirmed by MRI/CT 0-6 months prior to participation.
  • Able to independently walk at least 10 meters (assistive devices permitted) and capable of following instructions will be required.

Exclusion Criteria:

  • Diagnosed with dementia
  • Absolute contraindications to exercise or MRI scanning
  • Significant disability (modified Rankin score \>3)
  • Severe untreated depression (Beck Depression Inventory II score \>28)
  • Participants will be excluded if they have been engaged in a structured exercise training program outside their regular in/out-patient hospital rehabilitation since suffering the stroke.
  • Co-morbidities that preclude exercise participation, pain worsened with exercise, and communication (e.g., severe aphasia) or behavioral issues limiting safe participation will also be reasons for exclusion.

Study details
    Stroke

NCT07445841

McGill University

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.